Cannabinoid discrimination and antagonism by CB1 neutral and inverse agonist antagonists

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 3, 2013, Pages 561-567

  Kangas, Brian D ^a   Delatte, Marcus S ^a   Vemuri, V Kiran ^b   Thakur, Ganesh A ^b   Nikas, Spyridon P ^b   Subramanian, Kumara V ^b   Shukla, Vidyanand G ^b   Makriyannis, Alexandros ^b   Bergman, Jack ^a  

^a MCLEAN HOSPITAL   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AM 4054; AM 4113; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; DRONABINOL; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL; SAIMIRI SCIUREUS; SQUIRREL MONKEY;

ANIMALS; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; LIGANDS; MALE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SAIMIRI; TETRAHYDROCANNABINOL;

EID: 84874441447     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.201962     Document Type: Article

References (48)

1. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, and Stoch A, et al. (2008) The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78.
2. Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, and Meehan AG, et al. (2010) A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: A high-dose study. Int J Obes (Lond) 34:919-935.
3. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br Pharmacol Chemother 14:48-58.
4. Bergman J and Spealman RD (1988) Behavioral effects of histamine H1 antagonists: Comparison with other drugs and modification by haloperidol. J Pharmacol Exp Ther 245:471-478.
5. Breivogel CS and Childers SR (2000) Cannabinoid agonist signal transduction in rat brain: Comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 295:328-336.
6. Burkey TH, Quock RM, Consroe P, Roeske WR, and Yamamura HI (1997) delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. Eur J Pharmacol 323:R3-R4.
7. Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, Makriyannis A, and Sharkey KA (2007) A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293:R2185-R2193.
8. Cluny NL, Chambers AP, Vemuri VK, Wood JT, Eller LK, Freni C, Reimer RA, Makriyannis A, and Sharkey KA (2011) The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 97:537-543.
9. Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, Lutz B, Zimmer A, Parker LA, and Makriyannis A, et al. (2010) A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 161:629-642.
10. Compton DR, Aceto MD, Lowe J, and Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): Inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594.
11. Desai RI, Thakur GA, Vemuri VK, Bajaj S, Makriyannis A, and Bergman J (2012) Behavioral effects of cannabinoid and non-cannabinoid drugs during chronic CB1 agonist treatment. J Pharmacol Exp Ther DOI:10.1124/jpet.112.198374 [published ahead of print].
12. Després JP, Golay A, and Sjöström L; Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134.
13. Dykstra LA, Bertalmio AJ, and Woods JH (1988) Discriminative and analgesic effects of mu and kappa opioids: In vivo pA2 analysis, in Transduction Mechanisms of Drug Stimuli (Colpaert FC and Balster RL eds) pp 107-121, Springer-Verlag, Berlin.
14. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, and Volkow ND (1999) Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288:478-483.
15. Herd JA, Morse WH, Kelleher RT, and Jones LG (1969) Arterial hypertension in the squirrel monkey during behavioral experiments. Am J Physiol 217:24-29.
16. Järbe TUC, Tai S, LeMay BJ, Nikas SP, Shukla VG, Zvonok A, and Makriyannis A (2012) AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice. Psychopharmacology (Berl) 220:417-426.
17. Järbe TUC, Lamb RJ, Lin S, and Makriyannis A (2001) (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: Tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) 156:369-380.
18. Jutkiewicz EM, Makriyannis A, Vemuri K, and Bergman J (2010) Pro-depressantlike effects of CB1 receptor inverse agonists/antagonists in male Sprague-Dawley rats (Abstract). FASEB J 24 (Suppl):581.7.
19. Kirilly E, Gonda X, and Bagdy G (2012) CB1 receptor antagonists: New discoveries leading to new perspectives. Acta Physiol (Oxf) 205:41-60.
20. Lamb RJ, Järbe TUC, Makriyannis A, Lin S, and Goutopoulos A (2000) Effects of D 9-tetrahydrocannabinol, (R)-methanandamide, SR 141716,and d-amphetamine before and during daily D 9-tetrahydrocannabinol dosing. Eur J Pharmacol 398: 251-258.
21. Le Foll B, Forget B, Aubin HJ, and Goldberg SR (2008) Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: Insights from pre-clinical and clinical studies. Addict Biol 13:239-252.
22. McLaughlin PJ (2012) Reports of the death of CB1 antagonists have been greatly exaggerated: Recent preclinical findings predict improved safety in the treatment of obesity. Behav Pharmacol 23:537-550.
23. McMahon LR (2006a) Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating D9-tetrahydrocannabinol. J Pharmacol Exp Ther 319:1211-1218.
24. McMahon LR (2006b) Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with D9- tetrahydrocannabinol. Psychopharmacology (Berl) 188:306-314.
25. McMahon LR, Amin MR, and France CP (2005) SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys. Behav Pharmacol 16:363-372.
26. Meye FJ, Trezza V, Vanderschuren LJ, Ramakers GM, and Adan RA (2012) Neutral antagonism at the cannabinoid 1 receptor: A safer treatment for obesity. Mol Psychiatry DOI: 10.1038/mp.2012.145 [published ahead of print].
27. Nakamura-Palacios EM, Moerschbaecher JM, and Barker LA (1999) The pharmacology of SR 141716A: A Review. CNS Drug Rev 5:43-58.
28. National Research Council (2003) Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research, National Academies Press, Washington, DC.
29. Neubig RR, Spedding M, Kenakin T, and Christopoulos A; International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55:597-606.
30. Pacher P, Bátkai S, and Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462.
31. Padwal RS and Majumdar SR (2007) Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 369:71-77.
32. Paronis CA and Bergman J (1999) Apparent pA2 values of benzodiazepine antagonists and partial agonists in monkeys. J Pharmacol Exp Ther 290:1222-1229.
33. Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
34. Petitet F, Jeantaud B, Reibaud M, Imperato A, and Dubroeucq MC (1998) Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:PL1-PL6.
35. Proietto J, Rissanen A, Harp JB, Erondu N, Yu Q, Suryawanshi S, Jones ME, Johnson-Levonas AO, Heymsfield SB, and Kaufman KD, et al. (2010) A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: Low-dose study. Int J Obes (Lond) 34:1243-1254.
36. Rigotti NA, Gonzales D, Dale LC, Lawrence D, and Chang Y; CIRRUS Study Group (2009) A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: Efficacy, safety and weight gain. Addiction 104:266-276.
37. Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, and Parker LA (2007) Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 91:383-388.
38. Shen M and Thayer SA (1999) Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55:8-13.
39. Sim LJ, Hampson RE, Deadwyler SA, and Childers SR (1996) Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S] GTPgammaS autoradiography in rat brain. J Neurosci 16:8057-8066.
40. Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK, Peng Y, Olszewska T, Thakur GA, and Makriyannis A, et al. (2008) The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33: 946-955.
41. Spealman RD, Goldberg SR, Kelleher RT, Goldberg DM, and Charlton JP (1977) Some effects of cocaine and two cocaine analogs on schedule-controlled behavior of squirrel monkeys. J Pharmacol Exp Ther 202:500-509.
42. Spealman RD (1985) Discriminative-stimulus effects of midazolam in squirrel monkeys: Comparison with other drugs and antagonism by Ro 15-1788. J Pharmacol Exp Ther 235:456-462.
43. Traynor K (2007) Panel advises against rimonabant approval. Am J Health Syst Pharm 64:1460-1461.
44. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, and Rössner S; RIO-Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397.
45. Ward SJ and Raffa RB (2011) Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring) 19:1325-1334.
46. Wiley JL, Barrett RL, Britt DT, Balster RL, and Martin BR (1993) Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9-11-tetrahydrocannabinol in rats and rhesus monkeys. Neuropharmacology 32:359-365.
47. Wiley JL, Lowe JA, Balster RL, and Martin BR (1995) Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6.
48. Woods JH, Winger G, and France CP (1992) Use of in vivo apparent pA2 analysis in assessment of opioid abuse liability. Trends Pharmacol Sci 13:282-286.